Abstract
Nine novel mono-oxime reactivators bearing xylene linker were synthesized in an effort to improve previously prepared xylene bisoximes and monocarbamoyl-monooximes. The novel compounds were tested in vitro on the model of tabun-, paraoxon-, methylparaoxon- and DFP-inhibited human erythrocyte AChE. Their reactivation ability was compared to pralidoxime, asoxime, obidoxime and two previously prepared xylene linked bisoximes (K107, K108). All compounds showed minimal reactivation of tabun-inhibited AChE at selected concentration scale. This finding was explained by molecular modelling study. Bisoximes obidoxime and K108 resulted as the best reactivators for paraoxon-, methylparaoxon- and DFP-inhibited AChE. The loss of nonoxime moiety lead to the loss of reactivation ability within the novel compounds. Though the novel reactivators did not exceed previously known compounds, they confirmed former SAR findings for xylene-linked AChE reactivators.
Keywords: Acetylcholinesterase, tabun, DFP, pesticide, reactivator, oxime, xylene linker.
Medicinal Chemistry
Title:Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase
Volume: 12 Issue: 4
Author(s): Kamil Musilek, Jan Hambalek, Ondrej Holas, Vlastimil Dohnal and Kamil Kuca
Affiliation:
Keywords: Acetylcholinesterase, tabun, DFP, pesticide, reactivator, oxime, xylene linker.
Abstract: Nine novel mono-oxime reactivators bearing xylene linker were synthesized in an effort to improve previously prepared xylene bisoximes and monocarbamoyl-monooximes. The novel compounds were tested in vitro on the model of tabun-, paraoxon-, methylparaoxon- and DFP-inhibited human erythrocyte AChE. Their reactivation ability was compared to pralidoxime, asoxime, obidoxime and two previously prepared xylene linked bisoximes (K107, K108). All compounds showed minimal reactivation of tabun-inhibited AChE at selected concentration scale. This finding was explained by molecular modelling study. Bisoximes obidoxime and K108 resulted as the best reactivators for paraoxon-, methylparaoxon- and DFP-inhibited AChE. The loss of nonoxime moiety lead to the loss of reactivation ability within the novel compounds. Though the novel reactivators did not exceed previously known compounds, they confirmed former SAR findings for xylene-linked AChE reactivators.
Export Options
About this article
Cite this article as:
Musilek Kamil, Hambalek Jan, Holas Ondrej, Dohnal Vlastimil and Kuca Kamil, Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase, Medicinal Chemistry 2016; 12 (4) . https://dx.doi.org/10.2174/1573406411666151002125640
DOI https://dx.doi.org/10.2174/1573406411666151002125640 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Computer-Aided Drug Design Applied to Beta and Gamma Secretase Inhibitors-Perspectives for New Alzheimer Disease Therapy
Current Enzyme Inhibition Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Luteolin Antagonizes Angiotensin II-Dependent Proliferation and Collagen Synthesis of Cultured rat Cardiac Fibroblasts
Current Pharmaceutical Biotechnology The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets The Sirtuin Inhibitor Nicotinamide Enhances Neuronal Cell Survival During Acute Anoxic Injury Through AKT, BAD, PARP, and Mitochondrial Associated "Anti-Apoptotic" Pathways
Current Neurovascular Research Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of Drug Addiction
CNS & Neurological Disorders - Drug Targets Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets The Shock of the New: Progress in Schizophrenia Genomics
Current Genomics Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design The Use of Naltrexone in Dermatology. Current Evidence and Future Directions
Current Drug Targets SIRT1 Deacetylase Activity and the Maintenance of Protein Homeostasis in Response to Stress: An Overview
Protein & Peptide Letters Cannabinoids and Sensory Neurones
Current Neuropharmacology Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
Current Medicinal Chemistry Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design
Current Alzheimer Research Is There a Placebo Problem in Antidepressant Trials?
Current Topics in Medicinal Chemistry Preparing for Racial Discrimination and Moving beyond Reactive Coping: a Systematic Review
Current Psychiatry Research and Reviews Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets Brain Structural Effects of Antidepressant Treatment in Major Depression
Current Neuropharmacology Indium Salt-Promoted Organic Reactions
Current Organic Chemistry